Effects of mirabegron on JJ stent‐related symptoms: A multicentric study

Çınar, Önder; Tanıdır, Yılören; Özer, Selçuk; Cizmeci, Sezer; Erbatu, Oğuzcan; Özdemir, Turan; Girgin, Reha; Ongün, Şakir; Üçer, Oktay; Kızılay, Fuat; Şen, Volkan; İrer, Bora; Bozkurt, Ozan

doi:10.1111/ijcp.13857

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies have explored options such as changing the stent material or loading it with analgesic substances [5]. Additionally, research has shown that alpha blockers, anticholinergics, and beta-3 agonists can also reduce stent-related symptoms [6,7].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Evaluation of the Effect of Balneotherapy (Spa Treatment) on Lower Urinary Tract Symptoms Associated with JJ Stents: A prospective placebo-controlled study

ERGİN,

Öztürk,

Sancı

et al. 2024

Preprint

View full text Add to dashboard Cite

We aimed to assess the effectivity of balneotherapy (spa treatment) on lower urinary tract symptoms associated with JJ stents. Prospectively, the patients who underwent unilateral ureteral stone treatment and ureteral JJ stent placement were divided into 3 groups after the operation: Control, Tolterodine and Balneotherapy groups. The Control group was not receive to any pharmacological intervention, while the Tolterodine group was administered a daily dose of 4 mg of Tolterodine Sustained Release (SR) tablet, and the Balneotherapy group underwent balneotherapy (spa treatment) sessions three times per week, each lasting between half an hour and one hour. Post-operatively 1st week and 4th week ureteral stent symptom scores were measured using use of the Ureteral Stent Symptom Questionnaire (USSQ). A total of 54, 56 and 53 patients were included respectively. When the groups were compared to each other in the 4th week, there was a statistically significant difference between the scores of the first week and the fourth week after treatment in the tolterodine and balneotherapy groups. The p-values were 0.001 and 0.004, respectively. Analgesic using, Urinary symptoms, Body pain scores of Tolterodin and balneotherapy (spa treatment) groups were found to be lower than the control group (p < .001). Balneotherapy (spa treatment) may provide symptom improvement in JJ-stent related complaints.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Evaluation of the Effect of Balneotherapy (Spa Treatment) on Lower Urinary Tract Symptoms Associated with JJ Stents: A prospective placebo-controlled study

ERGİN,

Öztürk,

Sancı

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Yavuz et al performed a prospective placebo-controlled study comparing tamsulosin and mirabegron with a lesser use of analgesics by patients in the mirabegron group, although no reduction was seen in urinary symptoms scores when compared with placebo 17 . Finally, Cinar et al described a significant reduction in USRS with the use of mirabegron as a monotherapy in a retrospective study 18 . Therefore, this is the first study that compares mirabegron with an antimuscarinic for USRS.…”

Section: Discussionmentioning

confidence: 95%

Mirabegron as effective as oxybutynin for ureteral stent symptoms

Jaworski

Mello

Ferreira

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time.METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/ day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences.RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05).A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin.CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.

show abstract